← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cartesian Therapeutics, Inc.
Gaithersburg, MD
$9,405,187
Total funding
6
Grants
Funding over time
peak $3.1M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,405,187 · 6
By mechanism
R44$8,957,137 · 4
R43$299,042 · 1
U44$149,008 · 1
Investigators at Cartesian Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)$1,496,118
R44 · FY2024 · NS
Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)$1,496,118
R44 · FY2025 · NS
Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)$1,154,358
R44 · FY2021 · NS
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome$999,491
R44 · FY2022 · HL
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome$998,742
R44 · FY2021 · HL
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)$988,226
R44 · FY2021 · CA
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)$988,226
R44 · FY2020 · CA
Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)$835,858
R44 · FY2020 · NS
Transient anti-BCMA CAR T-cells for Treatment of Multiple Myeloma$299,042
R43 · FY2018 · CA
Targeting BCMA+ Cells with RNA-engineered CAR T cells to treat Lupus: A Phase 2 clinical study$149,008
U44 · FY2024 · AI